The main measure of prevention and treatment of diabetic neuropathy is the achievement and maintenance of target values of glycemic values. Recommendations for the pathogenetic therapy of diabetic neuropathy (benfotiamine, aldolazoreductase inhibitors, thioctic acid, nerve growth factor, aminoguanidine, protein kinase C inhibitor) are being developed.